TomoTherapy cuts jobs
This article was originally published in Clinica
Executive Summary
TomoTherapy last week joined the ever-growing list of companies undertaking cost-cutting measures with the announcement it was reducing its workforce by 12%. The Madison, Wisconsin firm said it will do so by laying off existing staff as well as eliminating open job positions. TomoTherapy CEO Fred Robertson deemed the action as "difficult, but necessary" in light of the company's decelerating growth in the current difficult economic conditions. With its revenues dependent on the sales of expensive capital equipment like its Hi-Art radiation therapy system, the firm has been hit particularly hard by the global financial turmoil. The company posted disappointing third-quarter results in October and its shareholders are pushing it to liquidate its assets (see Clinica Nos 1327, p 22 & 1328, p 20).
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.